Skip to main content
. 2021 Jun 7;17(1):185–193. doi: 10.4103/1673-5374.314312

Figure 3.

Figure 3

ALDH2 agonist Alda-1 reduces neurovascular dysfunction and inflammation in the acute phase (72 hours) of SCI in wild type mice.

Representative whole spinal cords (A) and spectrophotometric quantification (B) of the amount of blood in homogenates, representative whole spinal cords (C) showing Evans blue dye extravasation into spinal cord and quantification of the Evans blue extravasation (D), levels of edema (spinal water content) (E), Western blot of the expression of ICAM-1 and GFAP (F) and densitometry of ICAM-1 and GFAP (G). Data are presented as the mean ± SD (n = 7). ***P < 0.001, vs. Sham; +P < 0.05, ++P < 0.01, vs. SCI (one-way analysis of variance with Tukey’s post hoc test). Alda-1: N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; ALDH2: aldehyde dehydrogenase 2; GFAP: glial fibrillary acidic protein; ICAM-1: intercellular adhesion molecule 1; SCI: spinal cord injury.